Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA clears Enterix' colorectal cancer FOBT (faecal occult blood test):

This article was originally published in Clinica

Executive Summary

Enterix has received US FDA 510(k) clearance for its !nSure faecal occult blood test (FOBT) for screening colorectal cancer. The immunochemical test addresses patient compliance-limiting deficiencies associated with existing FOBTs, says the company, which has headquarters in Falmouth, Maine, and in Sydney, Australia. Unlike other FOBTs, Enterix claims its test does not have dietary or medicinal restrictions, it is specific for lower intestinal bleeding and requires only two days of samples instead of three.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT069894

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel